Global Clinical Trial Supplies Market valued at $2.5 billion in 2021, is poised to grow at a decent CAGR of 8%

The global clinical trial supplies market includes services like packaging and labeling services, clinical supplies logistics & distribution, comparator sourcing, and clinical supplies management. The R&D expenditure by large pharma companies totaled a record $133 billion in 2021, an increase of 44% since 2016. With the rising R&D spending and the increasing complexity of clinical trials, Pharma/Biotech is looking to outsource more non-core activities related to clinical trials. Big Pharma is usually more reluctant to outsource than biotech, which is highly reliant on external partners for clinical development activities.

Increased Focus on Biologics which require Specialized Logistics Capabilities

The worldwide biologics market which is growing at ~15% far exceeds the overall pharmaceutical market growth. Biologics drugs require specialized logistics, distribution, storage, and monitoring capabilities as drugs are temperature sensitive. This further provides growth opportunities for CTS providers with proven expertise and capabilities in handling biologics.

Steady Growth in Clinical Trials Conducted

In 2021, new clinical trials started, across Phase I/II/III, representing a 21% increase over the previous year. Overall, the number of new clinical trials started grew by 7.1% between 2016 and 21. The growth in the clinical trials conducted would spur the demand for the clinical trial supply services like comparator sourcing, clinical logistics and supplies management.

Oncology – High Growth Therapeutic Area for Clinical Trial Supplies

In terms of therapeutic use, oncology is the leading and fastest-growing market segment. This is mainly attributed to the presence of a huge R&D pipeline of oncology drugs. Moreover, the majority of oncology drugs require temperature-sensitive distribution, which is expected to fuel the demand for cold chain distribution.

Decentralized Trials leading to an increased demand for Clinical Trial Supplies Market

Covid-19 pandemic has provided an impetus to clinical trials being conducted in a decentralized manner. Virtual trials have become more important than ever post Covid-19 pandemic. There were hardly any M&As related to virtual trials taking place before the pandemic, but the market observed ~10 M&A deals in 2020. The growing trend toward decentralized trials and the need for direct-from-patient and direct-to-patient logistics and distribution of samples/drugs/monitoring equipment make the role of CTS providers more critical in ensuring smooth & efficient progress of clinical studies.

Global Footprint and Coverage, a Key Differentiator

As companies face challenges in the recruitment of patients, clinical trials are increasingly conducted across more regions and sites. CTS providers with a global footprint and/or ability to service across North America/Europe and increasingly Asia/LATAM as well, are in great demand.

Competitive Landscape Analysis: Clinical Trial Supplies Market

The global clinical trial supplies market is highly fragmented with the presence of large, integrated CDMOs as well as smaller players. CROs are also looking to expand their service scope to clinical trial manufacturing and also clinical trial supplies distribution & logistics as a vertical integration strategy.

Some of the top and upcoming players operating in the global clinical trial supplies market are Thermo Fisher Scientific, Catalent, Parexel, Almac Group, Clinigen, Marken (UPS), Piramal, UDG Healthcare, Klifo, Capsugel (Lonza), Recipharm, N-SIDE, Ancillare, and Biocair.

Get Customized Research Report on Clinical Trial Supplies Market @ https://meditechinsights.com/clinical-trial-supplies-market/

Comments

Post a Comment

Popular posts from this blog

Global Healthcare Companion Robots Market valued at about $3 billion (2020), is growing at a lucrative CAGR close to 20% through 2020-2025

Companion robots offer companionship and emotional support for the children, elderly, and disabled people. Over the years, the improvements in sensors, actuators, and AI have led to rise in interest in healthcare companion robots market. Rising aging population, the rising cost of elder care, and shortage of caregivers The population across the globe is aging and the number of caregivers in relation to the aging population is declining. In Japan, there will be an estimated shortage of 1 million caregivers by 2025. Moreover, the cost of elder care is also rising. Between 2019 and 2020, the cost of in-home care jumped by about 4.4%; assisted living costs surged by 6.2%; and nursing home costs increased by 3%. The use of robots instead could help reduce this cost. For instance, a monthly service contract for Stevie (a robot developed by Trinity College, Dublin) would likely run between 50-60% of the cost of hiring a human to do the same tasks, as per their claim. “The growing dispar...
Read more

Global Mycoplasma Testing Market is slated to see a lucrative growth rate of 11% by 2027

Mycoplasmas are the smallest known free-living microorganisms and are frequent contaminants of mammalian cell cultures. For the safety and purity of vaccines and other biological cell-derived products, it is crucial that the cell substrates and unprocessed bulk materials are free of adventitious agents, including mycoplasma.  In many cases, mycoplasmas vary from other forms of bacteria, making them difficult to culture and identify. Testing is done to detect mycoplasma like Mycoplasma hominis, Mycoplasma genitalium, Mycoplasma pneumoniae, and Ureaplasma urealyticum which can cause nongonococcal urethritis (NGU), prostate inflammation (prostatitis), vaginal discharge, and pelvic inflammatory disease (PID) in both men and women. Rising Concerns of Cell Culture Contamination to Trigger the Growth of the Global Mycoplasma Testing Market Mycoplasmas randomly contaminate the fluids used in the bioprocessing and cell culture. It is commonly known that primary cell cultures have a minimum...
Read more

Global Obesity Drugs Market valued at $2.3 billion in 2022, is expected to Witness a Healthy Growth of 25% by 2027

Obesity and overweight are defined as gain of additional fat thus leading to a number of diseases, which can be measured by using body mass index (BMI) as a baseline. A BMI of over 30 is generally considered as obese and a BMI of over 25 is considered as overweight. Obesity is a major risk factor to various diseases such as diabetes, heart diseases, and cancer; approximately over 650 million obese patients living across the world as as projected by World Health Organization (WHO). Rising Obese and Overweight Population to Trigger the Demand of Obesity Drugs Market Obesity is one of the topmost contributors to a number of medical diseases such as heart diseases, stroke, cancer and diabetes. World Obesity Atlas 2022 forecasted the growth of global obese population to be 16.1% in 2025, accounting for 892 million people which will further reach 1,025 million by 2030 with a healthy growth rate of 17.5% in 2030.  Some of the regional obesity burden estimated by World Obesity Atlas 202...
Read more